Colonic Perforation After Treatment With Nivolumab in Esophageal Cancer: A Case Report
Annals of Coloproctology
;
: S39-S43, 2021.
Article
in English
| WPRIM
| ID: wpr-896751
ABSTRACT
With the advent of checkpoint inhibitors, it has opened up opportunities for numerous cancer patients. However, as is the case with every treatment, complications need to be weighed. Gastrointestinal adverse effects, such as diarrhea and colitis are well-known complications for checkpoint inhibitors. In severe cases, colitis-induced colonic perforation may occur with an estimation of 1.0% to 1.5% in anti-CTLA-4 antibodies. However, only a handful of cases of such devastating complications have been reported in anti-PD-1 antibodies such as pembrolizumab and nivolumab. We here report a case of intestinal perforation in a patient treated with nivolumab.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
English
Journal:
Annals of Coloproctology
Year:
2021
Type:
Article
Similar
MEDLINE
...
LILACS
LIS